<p>Compass Therapeutics, Inc.（纳斯达克代码：CMPX - 获取免费报告）内部人士 Jonathan Anderman 于 4 月 7 日（星期一）购买了 20,000 股 Compass Therapeutics 股票，交易价格为每股平均 1.54 美元，总价值为 30,800.00 美元。完成购买后，该内部人士现在持有该公司 21,000 股股票，价值 32,340 美元。此次交易使其持股增加了 2,000.00%。该购买在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。</p>
<p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
<h2>Compass Therapeutics 股价上涨 3.5%</h2>
<ul>
<li>分析师仍看好前三大高动量公司</li>
</ul>
<p>在周二的午盘交易中，纳斯达克代码 CMPX 的股票上涨了 0.06 美元，达到了 1.63 美元。该股票的交易量为 371,628 股，而其平均交易量为 1,945,865 股。该股票的市值为 2.2471 亿美元，市盈率为-4.39，贝塔值为 1.40。Compass Therapeutics, Inc.的 12 个月最低价为 0.77 美元，最高价为 4.08 美元。该公司的 50 日移动平均价格为 2.73 美元，200 日移动平均价格为 2.11 美元。</p>
<p>Compass Therapeutics（纳斯达克代码：CMPX - 获取免费报告）最近于 2 月 27 日（星期四）发布了其财报。该公司报告本季度每股收益（EPS）为-0.11 美元，低于分析师一致预期的-0.10 美元，差距为 0.01 美元。平均而言，股票研究分析师预计 Compass Therapeutics, Inc.在当前年度的每股收益将为-0.36 美元。</p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近调整了对该股票的持有。Tower Research Capital LLC TRC 在第四季度将其在 Compass Therapeutics 的持股增加了 298.0%。Tower Research Capital LLC TRC 目前持有该公司 17,251 股股票，价值 25,000 美元，此前在上个季度购买了 12,917 股。Independent Advisor Alliance 在第四季度以约 26,000 美元的价格收购了 Compass Therapeutics 的新头寸。BNP Paribas Financial Markets 在第四季度以约 27,000 美元的价格购买了 Compass Therapeutics 的新股份。Intech Investment Management LLC 在第三季度以约 30,000 美元的价格收购了 Compass Therapeutics 的新股份。最后，Mariner LLC 在第四季度以约 30,000 美元的价格购买了 Compass Therapeutics 的新头寸。目前 68.43% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师升级和降级</h2>
<p>CMPX 成为多份分析师报告的主题。Jefferies Financial Group 在 2 月 10 日的研究报告中将 Compass Therapeutics 的目标价格从 7.00 美元上调至 8.00 美元，并给予该股票 “买入” 评级。Wedbush 在 4 月 1 日的研究报告中重申了 “跑赢大盘” 评级，并对 Compass Therapeutics 的股票设定了 8.00 美元的目标价格。Leerink Partners 在 4 月 1 日的研究报告中将 Compass Therapeutics 的评级从 “持有” 上调至 “强烈买入”。Leerink Partners 在 4 月 2 日的研究报告中将 Compass Therapeutics 的评级从 “市场表现” 上调至 “跑赢大盘”，并将该公司的目标价格从 4.00 美元上调至 6.00 美元。最后，D. Boral Capital 在 4 月 1 日的研究报告中重申了 “买入” 评级，并对 Compass Therapeutics 的股票设定了 32.00 美元的目标价格。八位分析师对该股票给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “买入”，共识目标价格为 13.38 美元。</p>
<p><strong>获取我们关于 CMPX 的最新研究报告</strong></p>
<h2>Compass Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Compass Therapeutics, Inc.是一家临床阶段的肿瘤学生物制药公司，专注于开发抗体基础的治疗方法，以治疗美国的各种人类疾病。该公司的主要产品候选包括 CTX-009，一种双特异性抗体，阻断 Delta-like ligand 4（Notch-1 的配体）和血管内皮生长因子 A 信号通路，这些通路对血管生成和肿瘤血管化至关重要；以及 CTX-471，一种 IgG4 单克隆抗体，是 CD137 的激动剂，CD137 是免疫细胞上的一个关键共刺激受体。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Compass Therapeutics</li>
<li>10 只最佳航空公司股票</li>
<li>PayPal 股票：太便宜而无法忽视，太强大而无法错过</li>
<li>3 只杂货股票证明它们仍然是必需品</li>
<li>Progress Software：在 AI 革命的推动下取得进展</li>
<li>如何使用股票筛选器寻找股票</li>
<li>英特尔 - 台湾半导体联盟推动反转希望</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Compass Therapeutics 吗？</h2>
<p>在考虑 Compass Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Compass Therapeutics 并不在名单上。</p>
<p>虽然 Compass Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CMPX

<p>Compass Therapeutics, Inc.（纳斯达克代码：CMPX）的内部人士 Jonathan Anderman 于 4 月 7 日以每股 1.54 美元的价格购买了 20,000 股，总计 30,800 美元。这次收购使他的持股增加到 21,000 股，价值 32,340 美元，标志着其持仓增加了 2,000%。该交易已向美国证券交易委员会（SEC）披露。购买后，CMPX 的股价上涨了 3.5%，达到 1.63 美元。分析师对该股票维持 “买入” 评级，普遍目标价为 13.38 美元</p>

<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) insider Jonathan Anderman acquired 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Monday, April 7th. The stock was purchased at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the purchase, the insider now owns 21,000 shares in the company, valued at $32,340. The trade was a 2,000.00 % increase in their position. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc.（纳斯达克代码：CMPX - 获取免费报告）内部人士 Jonathan Anderman 于 4 月 7 日（星期一）购买了 20,000 股 Compass Therapeutics 股票，交易价格为每股平均 1.54 美元，总价值为 30,800.00 美元。完成购买后，该内部人士现在持有该公司 21,000 股股票，价值 32,340 美元。此次交易使其持股增加了 2,000.00%。该购买在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。</p>
</div><p>Get <strong>Compass Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
</div><h2>Compass Therapeutics Trading Up 3.5 %</h2>
<div class="lb-trans"><h2>Compass Therapeutics 股价上涨 3.5%</h2>
</div><ul>
<li>Top 3 High-Momentum Companies Analysts Are Still Bullish On</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师仍看好前三大高动量公司</li>
</ul>
</div><p>Shares of NASDAQ:CMPX traded up $0.06 during midday trading on Tuesday, hitting $1.63. 371,628 shares of the stock were exchanged, compared to its average volume of 1,945,865. The stock has a market cap of $224.71 million, a P/E ratio of -4.39 and a beta of 1.40. Compass Therapeutics, Inc. has a twelve month low of $0.77 and a twelve month high of $4.08. The company has a 50 day moving average price of $2.73 and a 200-day moving average price of $2.11.</p>
<div class="lb-trans"><p>在周二的午盘交易中，纳斯达克代码 CMPX 的股票上涨了 0.06 美元，达到了 1.63 美元。该股票的交易量为 371,628 股，而其平均交易量为 1,945,865 股。该股票的市值为 2.2471 亿美元，市盈率为-4.39，贝塔值为 1.40。Compass Therapeutics, Inc.的 12 个月最低价为 0.77 美元，最高价为 4.08 美元。该公司的 50 日移动平均价格为 2.73 美元，200 日移动平均价格为 2.11 美元。</p>
</div><p>Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). On average, equities research analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.</p>
<div class="lb-trans"><p>Compass Therapeutics（纳斯达克代码：CMPX - 获取免费报告）最近于 2 月 27 日（星期四）发布了其财报。该公司报告本季度每股收益（EPS）为-0.11 美元，低于分析师一致预期的-0.10 美元，差距为 0.01 美元。平均而言，股票研究分析师预计 Compass Therapeutics, Inc.在当前年度的每股收益将为-0.36 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC boosted its holdings in shares of Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after purchasing an additional 12,917 shares during the last quarter. Independent Advisor Alliance acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at about $26,000. BNP Paribas Financial Markets purchased a new stake in shares of Compass Therapeutics during the 4th quarter worth about $27,000. Intech Investment Management LLC acquired a new stake in Compass Therapeutics during the 3rd quarter worth approximately $30,000. Finally, Mariner LLC purchased a new position in Compass Therapeutics in the fourth quarter valued at approximately $30,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该股票的持有。Tower Research Capital LLC TRC 在第四季度将其在 Compass Therapeutics 的持股增加了 298.0%。Tower Research Capital LLC TRC 目前持有该公司 17,251 股股票，价值 25,000 美元，此前在上个季度购买了 12,917 股。Independent Advisor Alliance 在第四季度以约 26,000 美元的价格收购了 Compass Therapeutics 的新头寸。BNP Paribas Financial Markets 在第四季度以约 27,000 美元的价格购买了 Compass Therapeutics 的新股份。Intech Investment Management LLC 在第三季度以约 30,000 美元的价格收购了 Compass Therapeutics 的新股份。最后，Mariner LLC 在第四季度以约 30,000 美元的价格购买了 Compass Therapeutics 的新头寸。目前 68.43% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>CMPX has been the topic of a number of analyst reports. Jefferies Financial Group lifted their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, February 10th. Wedbush reaffirmed an &#34;outperform&#34; rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Leerink Partnrs raised shares of Compass Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Tuesday, April 1st. Leerink Partners raised Compass Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and increased their price target for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Finally, D. Boral Capital restated a &#34;buy&#34; rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $13.38.</p>
<div class="lb-trans"><p>CMPX 成为多份分析师报告的主题。Jefferies Financial Group 在 2 月 10 日的研究报告中将 Compass Therapeutics 的目标价格从 7.00 美元上调至 8.00 美元，并给予该股票 “买入” 评级。Wedbush 在 4 月 1 日的研究报告中重申了 “跑赢大盘” 评级，并对 Compass Therapeutics 的股票设定了 8.00 美元的目标价格。Leerink Partners 在 4 月 1 日的研究报告中将 Compass Therapeutics 的评级从 “持有” 上调至 “强烈买入”。Leerink Partners 在 4 月 2 日的研究报告中将 Compass Therapeutics 的评级从 “市场表现” 上调至 “跑赢大盘”，并将该公司的目标价格从 4.00 美元上调至 6.00 美元。最后，D. Boral Capital 在 4 月 1 日的研究报告中重申了 “买入” 评级，并对 Compass Therapeutics 的股票设定了 32.00 美元的目标价格。八位分析师对该股票给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “买入”，共识目标价格为 13.38 美元。</p>
</div><p><strong>Get Our Latest Research Report on CMPX</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 CMPX 的最新研究报告</strong></p>
</div><h2>Compass Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Compass Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc.是一家临床阶段的肿瘤学生物制药公司，专注于开发抗体基础的治疗方法，以治疗美国的各种人类疾病。该公司的主要产品候选包括 CTX-009，一种双特异性抗体，阻断 Delta-like ligand 4（Notch-1 的配体）和血管内皮生长因子 A 信号通路，这些通路对血管生成和肿瘤血管化至关重要；以及 CTX-471，一种 IgG4 单克隆抗体，是 CD137 的激动剂，CD137 是免疫细胞上的一个关键共刺激受体。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Compass Therapeutics</li>
<li>10 Best Airline Stocks to Buy</li>
<li>PayPal Stock: Too Cheap to Ignore, Too Strong to Miss</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Progress Software: Making Progress Driven by the AI Revolution</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Compass Therapeutics</li>
<li>10 只最佳航空公司股票</li>
<li>PayPal 股票：太便宜而无法忽视，太强大而无法错过</li>
<li>3 只杂货股票证明它们仍然是必需品</li>
<li>Progress Software：在 AI 革命的推动下取得进展</li>
<li>如何使用股票筛选器寻找股票</li>
<li>英特尔 - 台湾半导体联盟推动反转希望</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Compass Therapeutics 吗？</h2>
</div><p>Before you consider Compass Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Compass Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Compass Therapeutics 并不在名单上。</p>
</div><p>While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Compass Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

乔纳森·安德曼购买了 20,000 股 Compass Therapeutics, Inc.（纳斯达克代码：CMPX）的股票